The global effort to find a cure for Alzheimer’s disease has seen a 35% increase in the number of clinical trials and a 40% increase in therapies being tested since 2016, according to a new report from a UNLV researcher.

In 2019, researchers at UNLV, the University of San Diego and Amsterdam University reported that about 99% of Alzheimer’s clinical trials had failed. After decades of setbacks, however, newer treatments are beginning to show success in clinical trials and are now moving through regulatory review. Scientists say these incremental advances could start to shift the trajectory of the disease, even as the number of people diagnosed continues to grow.

Las Vegas medical school study shows 35% increase in clinical trials since 2016.

Axsome Therapeutics’ Auvelity expanded its label to include treating agitation in Alzheimer’s disease patients. It’s just the second FDA-approved drug for this indication, and Axsome’s pill has a safety advantage.

Four years after gaining FDA approval for Auvelity to treat major depressive disorder (MDD), Axsome Therapeutics has tacked on a second nod in the United States for the first-in-class medicine to treat agitation associated with dementia caused by Alzheimer’s disease.

The agency’s decision marks the first approval of a drug with this specific mechanism of action for one of the most burdensome and clinically challenging symptoms of the disease.

Providers of mental health support and families of patients fear the dire consequences that will come from changes to insurance coverage

Up to 76% of patients with Alzheimer’s disease experience agitation, including pacing, restlessness and verbal or physical aggression.

Two guests who stayed at Wynn Las Vegas contracted Legionnaires’ disease, a severe type of pneumonia, in separate instances.

Organizers said mental health will be a key focus of the summit.

An eye mask, earplugs, and a same-day workout can all increase your odds.

On the morning of March 20, medical students at UNLV’s Kirk Kerkorian School of Medicine gathered with their families in a room buzzing with nervous energy. At noon Eastern time, along with tens of thousands of peers at medical schools across the country, they tore open envelopes to learn where they would spend the next three to seven years of their lives — and, in many cases, build their entire careers.